Literature DB >> 25246353

Late onset Lafora disease and novel EPM2A mutations: breaking paradigms.

Aurelio Jara-Prado1, Adriana Ochoa1, María Elisa Alonso1, Gabriel A Lima Villeda1, Francisca Fernández-Valverde2, Luis Ruano-Calderón2, Steven Vargas-Cañas2, Reyna M Durón3, Antonio V Delgado-Escueta4, Iris E Martínez-Juárez5.   

Abstract

Lafora disease (LD) is an autosomal recessive progressive myoclonus epilepsy with classic adolescent onset of stimuli sensitive seizures. Patients typically deteriorate rapidly with dementia, ataxia, vegetative failure and death by 25 years of age. LD is caused by homozygous mutations in EPM2A or EPM2B genes. We found four novel mutations in EPM2A - three in exon 4 (Q247X, H265R G279C) and one in exon 1 (Y86D) - and a previously described mutation in exon 4 (R241X). These five EPM2A mutations were found in four index cases and affected relatives. Patient 1 with classic LD was doubly heterozygous for H265R and R241X in exon 4; while Patient 2, who also had classic LD, was homozygous for Q247X in exon 4. Patient 3 with classic LD was homozygous for Y86D in exon 1, but the same mutation in his affected brother manifested an atypical earlier childhood onset. For the first time, we describe a later onset and slower progression of EPM2A-deficient LD seen in Patient 4 and her three sisters who were doubly heterozygous for R241X and G279C in exon 4. In these sisters, seizures started later at 21 to 28 years of age and progressed slowly with patients living beyond 30 years of age. Our observations suggest that variations in phenotypes of EPM2A-deficient LD, like an earlier childhood or adolescent or later adult onset with a rapid or slower course, depend on a second modifying factor separate from pathogenicity or exon location of EPM2A mutations. A modifying gene amongst the patient's genetic background or environmental factors may condition age of onset and rapid or slow progression of LD.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atypical phenotype; EPM2A; Lafora disease; Late onset; Slow progression

Mesh:

Substances:

Year:  2014        PMID: 25246353     DOI: 10.1016/j.eplepsyres.2014.08.017

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  10 in total

Review 1.  Lafora disease: from genotype to phenotype.

Authors:  Rashmi Parihar; Anupama Rai; Subramaniam Ganesh
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

Review 2.  Lafora disease - from pathogenesis to treatment strategies.

Authors:  Felix Nitschke; Saija J Ahonen; Silvia Nitschke; Sharmistha Mitra; Berge A Minassian
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

3.  A novel EPM2A mutation yields a slow progression form of Lafora disease.

Authors:  Maria Adelaida Garcia-Gimeno; Pilar Natalia Rodilla-Ramirez; Rosa Viana; Xavier Salas-Puig; M Kathryn Brewer; Matthew S Gentry; Pascual Sanz
Journal:  Epilepsy Res       Date:  2018-07-21       Impact factor: 3.045

Review 4.  Myoclonus-Ataxia Syndromes: A Diagnostic Approach.

Authors:  Malco Rossi; Sterre van der Veen; Marcelo Merello; Marina A J Tijssen; Bart van de Warrenburg
Journal:  Mov Disord Clin Pract       Date:  2020-11-03

5.  Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis.

Authors:  Luca Vignatelli; Francesca Bisulli; Federica Pondrelli; Lorenzo Muccioli; Laura Licchetta; Barbara Mostacci; Corrado Zenesini; Paolo Tinuper
Journal:  Orphanet J Rare Dis       Date:  2021-08-16       Impact factor: 4.123

Review 6.  Pathogenesis of Lafora Disease: Transition of Soluble Glycogen to Insoluble Polyglucosan.

Authors:  Mitchell A Sullivan; Silvia Nitschke; Martin Steup; Berge A Minassian; Felix Nitschke
Journal:  Int J Mol Sci       Date:  2017-08-11       Impact factor: 5.923

7.  Extraneurological sparing in long-lived typical Lafora disease.

Authors:  Danielle Goldsmith; Berge A Minassian
Journal:  Epilepsia Open       Date:  2018-05-17

8.  An empirical pipeline for personalized diagnosis of Lafora disease mutations.

Authors:  M Kathryn Brewer; Maria Machio-Castello; Rosa Viana; Jeremiah L Wayne; Andrea Kuchtová; Zoe R Simmons; Sarah Sternbach; Sheng Li; Maria Adelaida García-Gimeno; Jose M Serratosa; Pascual Sanz; Craig W Vander Kooi; Matthew S Gentry
Journal:  iScience       Date:  2021-10-13

9.  A Novel Mutation in Lafora Disease and Update on Pathophysiology and Future Treatments.

Authors:  Douglas R Nordli; Chethan K Rao; Antonio V Delgado-Escueta; Fernando Galan
Journal:  Child Neurol Open       Date:  2022-10-05

Review 10.  Beneficial Effects of Metformin on the Central Nervous System, with a Focus on Epilepsy and Lafora Disease.

Authors:  Pascual Sanz; José Maria Serratosa; Marina P Sánchez
Journal:  Int J Mol Sci       Date:  2021-05-19       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.